Biovail’s Ralivia receives approvable letter

Share this article:
An item appearing in the December issue of Medical Marketing and Media (Pipeline, page 10) incorrectly stated that Biovail's Ralivia ER (tramadol hydrochloride) had received FDA approval.
Biovail has received an approvable letter from the FDA for the drug, but it has yet to be approved.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.